SANDOZ PRAVASTATIN TABLET
Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Súhrn charakteristických
(SPC)
16-02-2017
Niektoré dokumenty týkajúce sa tohto produktu nie sú momentálne k dispozícii, môžete poslať požiadavku na náš zákaznícky servis a my vás upozorníme hneď, ako ich dokážeme získať.
Poslať žiadosť.
Poslať žiadosť.
Aktívna zložka:
PRAVASTATIN SODIUM
Dostupné z:
SANDOZ CANADA INCORPORATED
ATC kód:
C10AA03
INN (Medzinárodný Name):
PRAVASTATIN
Dávkovanie:
40MG
Forma lieku:
TABLET
Zloženie:
PRAVASTATIN SODIUM 40MG
Spôsob podávania:
ORAL
Počet v balení:
30/100/250/500
Typ predpisu:
Prescription
Terapeutické oblasti:
HMG-COA REDUCTASE INHIBITORS
Prehľad produktov:
Active ingredient group (AIG) number: 0122563003; AHFS:
Stav Autorizácia:
CANCELLED POST MARKET
Dátum Autorizácia:
2017-05-29
Súhrn charakteristických
PRODUCT MONOGRAPH
PR
SANDOZ PRAVASTATIN
Pravastatin Sodium
10 mg, 20 mg and 40 mg tablets
Lipid Metabolism Regulator
Sandoz Canada Inc.
145 Jules-Léger
Date of Revision: February 16, 2017
Boucherville, QC, Canada
J4B 7K8
Control No. 202280
Sandoz Pravastatin
Page 2 of 41
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
......................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
5
WARNINGS AND PRECAUTIONS
..........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
11
DRUG INTERACTIONS
..........................................................................................................
15
DOSAGE AND ADMINISTRATION
......................................................................................
17
OVERDOSAGE
........................................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
18
STORAGE AND STABILITY
.................................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
..................................................... 20
PART II: SCIENTIFIC INFORMATION
...............................................................................
21
PHARMACEUTICAL INFORMATION
.................................................................................
21
CLINICAL TRIALS
............................................................................................................
Prečítajte si celý dokument
